Bausch + Lomb Corp.
BLCO
17.34
+0.16
+0.93%
Bausch + Lomb Corp.
US · BLCO
#1909 by market cap
Listed 2022
17.34
+0.16
+0.93%
Live - 5344 symbols - heartbeat 523s ago
· 2026-10-07 19:54
After-hours
17.34
0.00%
- Market cap
- 6.19B
- P/E (TTM)i
- -36.13
- P/Bi
- 0.97
- EPSi
- -1.02
- Div yieldi
- 0.00%
- 52W posi
- 65%
Reader sentiment
Are you bullish or bearish on BLCO?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 0.90, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +6.47% YoY
Margins
- Gross margin
- 59.81%
- Operating margin
- 3.69%
- Net margin
- -7.06%
Key ratios & quality
- Enterprise valuei
- 10.89B
- Altman Z-Scorei
- 0.90
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.67B | 3.78B | 3.41B | 3.77B | 3.77B | 4.15B | 4.79B | 5.10B |
| Gross profit | 2.35B | 2.45B | 2.13B | 2.30B | 2.25B | 2.50B | 2.92B | 3.05B |
| Selling & admin expenses | 1.33B | 1.38B | 1.25B | 1.39B | 1.48B | 1.74B | 2.08B | 2.23B |
| Research & development | 221.00M | 258.00M | 253.00M | 271.00M | 307.00M | 324.00M | 343.00M | 371.00M |
| Operating profit | 427.00M | 463.00M | 298.00M | 346.00M | 220.00M | 204.00M | 206.00M | 188.00M |
| Pretax profit | 417.00M | 399.00M | 290.00M | 318.00M | 73.00M | -166.00M | -234.00M | -317.00M |
| Tax | -302.00M | 96.00M | 307.00M | 125.00M | 58.00M | 82.00M | 71.00M | 35.00M |
| Net profit | 719.00M | 303.00M | -17.00M | 193.00M | 15.00M | -248.00M | -305.00M | -352.00M |
| Basic EPS | 2 | 1 | 0 | 1 | 0 | -1 | -1 | -1 |
| Diluted EPS | 2.03 | 0.85 | -0.05 | 0.52 | 0.02 | -0.74 | -0.90 | -1.02 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.14B | 1.28B | 1.28B | 1.41B | 1.24B | 1.39B |
| Gross profit | 655.00M | 753.00M | 771.00M | 872.00M | 761.00M | 867.00M |
| Selling & admin expenses | 563.00M | 579.00M | 528.00M | 564.00M | 544.00M | 588.00M |
| Research & development | 86.00M | 96.00M | 95.00M | 94.00M | 101.00M | 114.00M |
| Operating profit | -61.00M | 11.00M | 80.00M | 158.00M | 59.00M | 108.00M |
| Pretax profit | -180.00M | -147.00M | -3.00M | 13.00M | -64.00M | -11.00M |
| Tax | 31.00M | -89.00M | 22.00M | 71.00M | 6.00M | -1.00M |
| Net profit | -211.00M | -58.00M | -25.00M | -58.00M | -70.00M | -10.00M |
| Basic EPS | -1 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.60 | -0.18 | -0.08 | -0.16 | -0.20 | -0.04 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | -- | 1.70B | 1.65B | 1.64B | 2.14B | 2.74B | 2.79B | 2.98B |
| Cash & ST investments | -- | 192.00M | 238.00M | 174.00M | 354.00M | 331.00M | 305.00M | 383.00M |
| Inventory | -- | 592.00M | 616.00M | 572.00M | 628.00M | 1.03B | 1.04B | 976.00M |
| Total assets | -- | 11.47B | 11.27B | 10.82B | 11.14B | 13.44B | 13.47B | 14.02B |
| Total current liabilities | -- | 1.04B | 909.00M | 1.10B | 1.30B | 1.58B | 1.74B | 1.92B |
| Short-term debt | -- | -- | -- | 28.00M | 25.00M | 30.00M | 40.00M | 39.00M |
| Long-term debt | -- | -- | -- | -- | 2.41B | 4.53B | 4.74B | 5.04B |
| Total liabilities | -- | 1,436,000,000.00 | 1,278,000,000.00 | 1,421,000,000.00 | 4,043,000,000.00 | 6,522,000,000.00 | 6,925,000,000.00 | 7,503,000,000.00 |
| Total equity | -- | 10.03B | 9.99B | 9.40B | 7.10B | 6.92B | 6.54B | 6.52B |
| Retained earnings | -- | -- | -- | 0 | 6.00M | -254.00M | -571.00M | -931.00M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 2.69B | 2.85B | 2.86B | 2.98B | 2.78B | 2.92B |
| Cash & ST investments | 202.00M | 266.00M | 310.00M | 383.00M | 268.00M | 367.00M |
| Inventory | 1.03B | 1.05B | 1.01B | 976.00M | 977.00M | 999.00M |
| Total assets | 13.43B | 13.83B | 13.83B | 14.02B | 13.78B | 13.86B |
| Total current liabilities | 1.73B | 1.84B | 1.90B | 1.92B | 1.82B | 1.89B |
| Short-term debt | 40.00M | 28.00M | 28.00M | 39.00M | 39.00M | 43.00M |
| Long-term debt | 4.79B | 4.93B | 4.92B | 5.04B | 5.03B | 5.07B |
| Total liabilities | 6,995,000,000.00 | 7,324,000,000.00 | 7,332,000,000.00 | 7,503,000,000.00 | 7,328,000,000.00 | 7,415,000,000.00 |
| Total equity | 6.43B | 6.51B | 6.50B | 6.52B | 6.45B | 6.44B |
| Retained earnings | -783.00M | -845.00M | -873.00M | -931.00M | -1.00B | -1.02B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 763.00M | 799.00M | 522.00M | 873.00M | 345.00M | -17.00M | 232.00M | 283.00M |
| Depreciation & amortization | 495.00M | 469.00M | 442.00M | 415.00M | 379.00M | 382.00M | 436.00M | 421.00M |
| Free cash flow | 662.00M | 619.00M | 263.00M | 680.00M | 170.00M | -198.00M | -59.00M | -66.00M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 188.00M | 192.00M | 238.00M | 177.00M | 380.00M | 334.00M | 316.00M | 397.00M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -25.00M | 35.00M | 137.00M | 136.00M | 32.00M | 153.00M |
| Depreciation & amortization | 106.00M | 107.00M | 109.00M | 99.00M | 101.00M | 102.00M |
| Free cash flow | -135.00M | -54.00M | 63.00M | 60.00M | -68.00M | 82.00M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 215.00M | 272.00M | 332.00M | 397.00M | 279.00M | 378.00M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | 2.99 | -0.18 | 1.89 | 0.07 | -3.75 | -4.76 | -5.57 |
| ROA %i | -- | 2.60 | -0.16 | 1.65 | 0.05 | -2.12 | -2.36 | -2.62 |
| ROIC %i | -- | 2.98 | -0.20 | 1.89 | 1.03 | -0.95 | 0.08 | -0.11 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | 0.21 | -1.34 | -2.42 |
| EBIT margin %i | 11.65 | 12.26 | 8.73 | 9.19 | 5.81 | 2.82 | 3.44 | 2.04 |
| FCF / sales %i | 18.06 | 16.38 | 7.71 | 17.64 | 4.51 | -- | -- | -- |
| Current ratioi | -- | 1.64 | 1.82 | 1.49 | 1.65 | 1.74 | 1.60 | 1.55 |
| Quick ratioi | -- | 0.87 | 0.97 | 0.81 | 0.83 | 0.74 | 0.77 | 0.84 |
| Debt / assetsi | -- | -- | -- | 0.26 | 21.86 | 33.94 | 35.52 | 36.24 |
| LT debt / equityi | -- | -- | -- | -- | 34.28 | 66.16 | 73.29 | 78.21 |
| Interest coveragei | -- | -- | -- | -- | 1.50 | 0.41 | 0.41 | 0.25 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.90 | -0.09 | 6.71 | 8.36 | 10.62 |
| Net income CAGR (3Y) %i | -- | -- | -- | -36.48 | -72.80 | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | 0.90 | -35.00 | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -5.56 | -4.22 | -4.69 | -5.57 | -3.44 | -2.67 |
| ROA %i | -2.71 | -2.02 | -2.23 | -2.62 | -1.61 | -1.24 |
| ROIC %i | -0.36 | -0.03 | 0.44 | -0.11 | 0.24 | 0.47 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 1.45 | 0.51 | 1.63 | 2.04 | 4.28 | 6.09 |
| FCF / sales %i | -- | -- | -- | -- | 0.02 | 2.57 |
| Current ratioi | 1.56 | 1.55 | 1.51 | 1.55 | 1.53 | 1.55 |
| Quick ratioi | 0.70 | 0.73 | 0.74 | 0.84 | 0.75 | 0.81 |
| Debt / assetsi | 35.96 | 35.85 | 35.79 | 36.24 | 36.79 | 36.91 |
| LT debt / equityi | 75.29 | 76.57 | 76.56 | 78.21 | 78.87 | 79.55 |
| Interest coveragei | 0.18 | 0.06 | 0.19 | 0.25 | 0.53 | 0.83 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Vision Care is the largest reported line at 56.24% of revenue, across 3 reported segments.
- Pharmaceuticals follows at 25.39%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Vision Care56.24%
Pharmaceuticals25.39%
Surgical18.36%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.